Evercore ISI analyst Liisa Bayko maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target of $510.00. The company’s shares closed yesterday ...

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $492.47, moving +0.01% from the previous trading session. This move lagged the S&P 500's daily gain of 2.03%. Elsewhere ...

Ratings for Vertex Pharmaceuticals VRTX were provided by 18 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their ...

As previously reported, Cantor Fitzgerald assumed coverage of Vertex Pharmaceuticals (VRTX) with an Overweight rating and a price target of $535, up from $480. Vertex remains well-positioned with ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Vertex Pharmaceuticals wasn’t one of them. The 10 stocks that ...

Vertex Pharmaceuticals saw its share price rise by approximately 14% in the last quarter, a significant move considering the broader market's recent 1% decline. The company's legal challenges, such as ...